CA3021681C - USE OF BETA-AGONISTS OF THYROID HORMONES - Google Patents

USE OF BETA-AGONISTS OF THYROID HORMONES

Info

Publication number
CA3021681C
CA3021681C CA3021681A CA3021681A CA3021681C CA 3021681 C CA3021681 C CA 3021681C CA 3021681 A CA3021681 A CA 3021681A CA 3021681 A CA3021681 A CA 3021681A CA 3021681 C CA3021681 C CA 3021681C
Authority
CA
Canada
Prior art keywords
agonists
thyroid beta
thyroid
beta
2use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3021681A
Other languages
English (en)
French (fr)
Other versions
CA3021681A1 (en
Inventor
Brian Lian
Rochelle Hanley
Misha Dinerman
Mark Erion
Serge Boyer
Hongjian Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hongjian Jiang
Metabasis Therapeutics Inc
Viking Therapeutics Inc
Original Assignee
Hongjian Jiang
Metabasis Therapeutics Inc
Viking Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hongjian Jiang, Metabasis Therapeutics Inc, Viking Therapeutics Inc filed Critical Hongjian Jiang
Publication of CA3021681A1 publication Critical patent/CA3021681A1/en
Application granted granted Critical
Publication of CA3021681C publication Critical patent/CA3021681C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3021681A 2016-04-22 2017-04-24 USE OF BETA-AGONISTS OF THYROID HORMONES Active CA3021681C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326436P 2016-04-22 2016-04-22
US62/326,436 2016-04-22
PCT/US2017/029120 WO2017185087A1 (en) 2016-04-22 2017-04-24 Use of thyroid beta-agonists

Publications (2)

Publication Number Publication Date
CA3021681A1 CA3021681A1 (en) 2017-10-26
CA3021681C true CA3021681C (en) 2024-09-24

Family

ID=60116400

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3021681A Active CA3021681C (en) 2016-04-22 2017-04-24 USE OF BETA-AGONISTS OF THYROID HORMONES

Country Status (10)

Country Link
US (3) US11351183B2 (enExample)
EP (1) EP3445373B1 (enExample)
JP (1) JP6931042B2 (enExample)
KR (1) KR102407059B1 (enExample)
AU (1) AU2017252126B2 (enExample)
BR (1) BR112018071586A2 (enExample)
CA (1) CA3021681C (enExample)
ES (1) ES2992773T3 (enExample)
MX (1) MX385085B (enExample)
WO (1) WO2017185087A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992773T3 (en) 2016-04-22 2024-12-18 Viking Therapeutics Inc Use of thyroid beta-agonists
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
CA2543132A1 (en) 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
SG144145A1 (en) 2004-12-08 2008-07-29 Sirion Therapeutics Inc Methods, assays and compositions for treating retinol-related diseases
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
US20090042857A1 (en) 2006-02-20 2009-02-12 Masuo Yamaoka Novel Pharmaceutical
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
MX344807B (es) 2011-06-21 2017-01-09 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3).
JP2016517883A (ja) 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
JP2018510849A (ja) 2015-02-20 2018-04-19 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ ソベチロムの誘導体
JP6862459B2 (ja) 2016-02-29 2021-04-21 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ヒンジリッド容器およびブランク
KR102407053B1 (ko) 2016-04-22 2022-06-10 바이킹 테라퓨틱스 인코포레이티드 갑상선 베타-작용제의 사용
ES2992773T3 (en) 2016-04-22 2024-12-18 Viking Therapeutics Inc Use of thyroid beta-agonists
KR102331596B1 (ko) 2016-05-18 2021-11-25 오레곤 헬스 앤드 사이언스 유니버시티 소베티롬의 유도체

Also Published As

Publication number Publication date
CA3021681A1 (en) 2017-10-26
EP3445373A4 (en) 2019-12-18
JP2019515033A (ja) 2019-06-06
US12440502B2 (en) 2025-10-14
KR102407059B1 (ko) 2022-06-10
EP3445373A1 (en) 2019-02-27
WO2017185087A1 (en) 2017-10-26
MX385085B (es) 2025-03-14
ES2992773T3 (en) 2024-12-18
US20220257618A1 (en) 2022-08-18
US11951114B2 (en) 2024-04-09
AU2017252126A1 (en) 2018-11-08
JP6931042B2 (ja) 2021-09-01
MX2018012900A (es) 2019-07-01
BR112018071586A2 (pt) 2019-02-12
US20250000880A1 (en) 2025-01-02
AU2017252126B2 (en) 2023-02-09
US20190321379A1 (en) 2019-10-24
US11351183B2 (en) 2022-06-07
KR20190039027A (ko) 2019-04-10
EP3445373B1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
PT3807267T (pt) Agonistas do recetor da hormona da tiroide e usos dos mesmos
IL282076A (en) Thyroid hormone receptor agonists
IL279300A (en) 1-GLP agonist receptors and their use
IL279224A (en) 1-GLP agonist receptors and their use
PH12018501409A1 (en) Triple glucagon/glp-1/gip receptor agonist
MX2020003760A (es) Formulaciones de niraparib.
MX2020004015A (es) Composicion de control de fraguado para sistemas cementosos.
MX2020003217A (es) Coagonistas de accion prolongada de los receptores de glucagon y glp-1.
MX2017001554A (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias.
ZA202507395B (en) Semaglutide in cardiovascular conditions
MX2020004424A (es) Formulacion aerosolizable.
PT3612520T (pt) Derivados de isoxazol como agonistas de recetores nucleares e utilizações dos mesmos
SG11202103731QA (en) Radioligands for imaging the lpa1 receptor
CA3021681C (en) USE OF BETA-AGONISTS OF THYROID HORMONES
SG11202103776YA (en) Apparatus for delivery of radioembolization microspheres
EP3445769A4 (en) THYROID HORMONE RECEPTOR AGONIST AND ITS USE
CA3021677C (en) USE OF BETA-AGONISTS OF THYROID HORMONES
MY195657A (en) Liraglutide In Cardiovascular Conditions
MX2020003511A (es) Formulaciones orales de bendamustina.
IL277358A (en) Omniphilic nanovesicles based on modified polysaccharides for the delivery of active substances
MX2020003537A (es) Aplicador con una camara integrada.
HK40058390A (en) Thyroid hormone receptor beta agonist compounds
HK40055638A (en) Thyroid hormone receptor beta agonist compounds
GB201817943D0 (en) Galanin-2 receptor agonists
HK40005327A (en) Thyroid hormone receptor agonist and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220420

EEER Examination request

Effective date: 20220420

EEER Examination request

Effective date: 20220420

EEER Examination request

Effective date: 20220420

EEER Examination request

Effective date: 20220420

EEER Examination request

Effective date: 20220420

EEER Examination request

Effective date: 20220420

EEER Examination request

Effective date: 20220420

EEER Examination request

Effective date: 20220420

EEER Examination request

Effective date: 20220420